Education
About Us
Working with TipRanks
Follow Us
Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
RESEARCH TOOLSreports
Total Valuation
Allarity Therapeutics has a market cap or net worth of $16.06M. The enterprise value is ―.
Market Cap$16.06M
Enterprise Value―
Share Statistics
Allarity Therapeutics has 15,079,572 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15,079,572
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Allarity Therapeutics’s return on equity (ROE) is 4.33 and return on invested capital (ROIC) is 1682.61%.
Return on Equity (ROE)4.33
Return on Assets (ROA)-1.00
Return on Invested Capital (ROIC)1682.61%
Return on Capital Employed (ROCE)7.78
Revenue Per Employee0.00
Profits Per Employee-1.98M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Allarity Therapeutics is -55.31K. Allarity Therapeutics’s PEG ratio is >-0.01.
PE Ratio-55.31K
PS Ratio0.00
PB Ratio0.12
Price to Fair Value-239.28K
Price to FCF-0.29
Price to Operating Cash Flow-0.10
PEG Ratio>-0.01
Income Statement
In the last 12 months, Allarity Therapeutics had revenue of 0.00 and earned -11.90M in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit-37.00K
Operating Income-17.93M
Pretax Income-12.62M
Net Income-11.90M
EBITDA-12.08M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -15.82M and capital expenditures 0.00, giving a free cash flow of -15.82M billion.
Operating Cash Flow-15.82M
Free Cash Flow-15.82M
Free Cash Flow per Share-1.05
Dividends & Yields
Allarity Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change-94.04%
50-Day Moving Average0.98
200-Day Moving Average1.70
Relative Strength Index (RSI)52.86
Average Volume (3m)1.05M
Important Dates
Allarity Therapeutics upcoming earnings date is Nov 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 9, 2025
Next Earnings DateNov 12, 2025
Ex-Dividend Date―
Financial Position
Allarity Therapeutics as a current ratio of 0.14, with Debt / Equity ratio of 10.31%
Current Ratio0.14
Quick Ratio0.14
Debt to Market Cap<0.01
Net Debt to EBITDA-0.09
Interest Coverage Ratio-36.00
Taxes
In the past 12 months, Allarity Therapeutics has paid -717.00K in taxes.
Income Tax-717.00K
Effective Tax Rate0.06
Enterprise Valuation
Allarity Therapeutics EV to EBITDA ratio is -54.48K, with an EV/FCF ratio of -51.65K.
EV to Sales0.00
EV to EBITDA-54.48K
EV to Free Cash Flow-51.65K
EV to Operating Cash Flow-51.65K
Balance Sheet
Allarity Therapeutics has $18.46M in cash and marketable securities with $1.34M in debt, giving a net cash position of -$17.13M billion.
Cash & Marketable Securities$18.46M
Total Debt$1.34M
Net Cash-$17.13M
Net Cash Per Share-$1.14
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 89.29%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin89.29%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Allarity Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast99.43%